Comparative Efficacy of Two Dosages of Recombinant Hepatitis B Vaccine in Healthy Adolescents in India
Authors:
- Vijayakumar VeluVijayakumar Velu
- Subhadra NandakumarSNSubhadra Nandakumar
- Saravanan ShanmugamSSSaravanan Shanmugam
- Esaki Muthu ShankarESEsaki Muthu Shankar
- Sundararajan ThangavelSTSundararajan Thangavel
- Prasad Suryakant KulkarniPKPrasad Suryakant Kulkarni
- Sadras Panchatcharam ThyagarajanSTSadras Panchatcharam Thyagarajan
- 1 November 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (11) , 1038-1041
Abstract
Inclusion of hepatitis B vaccine in the Universal Programme of Immunization of all Asian and African countries is hampered by the economic burden on the health budget because of the cost of hepatitis B vaccines. Here we evaluated the immunogenicity, safety, efficacy, and the persistence of antibody to hepatitis B surface antigen (anti-HBs) titers of a new and a low cost recombinant hepatitis B vaccine GeneVac B, with 2 different dosages in healthy adolescents in India.GeneVac-B, a recombinant hepatitis B vaccine (Serum Institute of India, Pune, India), was administered in 10 or 20 microg dose intramuscularly to 2 groups of 100 healthy school-going adolescents at 0-, 1-, and 6-month intervals, who were followed up for 1 year. Group I received 20 mug doses whereas Group II received 10 mug doses. Blood samples were collected 1 month after each dose and 1 year after the third dose. The anti-HBs titers were assayed using commercially available kits to assess the immunogenicity of the 2 dosage schedules. Safety studies were also carried out.The geometric mean titer value of the anti-HBs titer 1 month after the third dose was 2629 (mlU/mL) in Group I and 1373 mlU/mL for Group II subjects. One year after the third dose, the persistence of anti-HBs in those who had received 20 mug was 2262 mlU/mL whereas it was 1039 mlU/mL in the group receiving 10 microg doses. All the subjects in both the groups were seroprotected at 1 year after vaccination. None of the vaccinees exhibited serious adverse reactions throughout the study period.The study demonstrated the immunogenicity of the recombinant hepatitis B vaccine, and confirms that the 0.5 mL (10 microg) dose of GeneVac B can be administered with satisfactory safety and immunogenicity to adolescents up to 19 years of age, reducing the cost to less than U.S. $1.00 per dose making it acceptable for the Universal Programme of Immunization of developing and under developed countries.Keywords
This publication has 19 references indexed in Scilit:
- Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adultsVaccine, 2006
- Hepatitis B Vaccine Administered to Children and Adolescents at Yearly IntervalsPediatrics, 1999
- Seroepidemiologic Survey for Hepatitis B Virus Infection in Taiwan: The Effect of Hepatitis B Mass ImmunizationThe Journal of Infectious Diseases, 1999
- Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in ChildrenNew England Journal of Medicine, 1997
- Vaccines to Prevent Viral HepatitisNew England Journal of Medicine, 1997
- Risks of Chronicity Following Acute Hepatitis B Virus Infection: A ReviewClinical Infectious Diseases, 1995
- Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescentsJournal of Adolescent Health, 1995
- Overview of clinical studies with hepatitis B vaccine made by recombinant DNAJournal of Infection, 1986
- HEPATITIS B VIRUS CARRIER STATE IN BLACK CHILDREN IN OVAMBOLAND: ROLE OF PERINATAL AND HORIZONTAL INFECTIONThe Lancet, 1984
- Materno-foetal transmission of hepatitis B in Saudi ArabiaJournal of Infection, 1984